| Resistance Measure . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . |
|---|---|---|---|---|---|---|---|---|
| S . | S . | R . | S . | S . | R . | R . | R . | |
| Poor outcome/total | 12/57 (21%) | 25/78 (28%) | 1/2 (50%) | 13/23 (57%) | ||||
| Resistance Measure . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . |
|---|---|---|---|---|---|---|---|---|
| S . | S . | R . | S . | S . | R . | R . | R . | |
| Poor outcome/total | 12/57 (21%) | 25/78 (28%) | 1/2 (50%) | 13/23 (57%) | ||||
Culture DST = resistant if moxifloxacin >0.5 mg/dL or if no moxifloxacin DST is available if levofloxacin DST shows resistance; gyr sequencing = resistant only if a high-level mutation is found as defined in the Methods.
Abbreviations: DST, drug susceptibility testing; R, resistant; S, sensitive; Seq, sequencing.
| Resistance Measure . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . |
|---|---|---|---|---|---|---|---|---|
| S . | S . | R . | S . | S . | R . | R . | R . | |
| Poor outcome/total | 12/57 (21%) | 25/78 (28%) | 1/2 (50%) | 13/23 (57%) | ||||
| Resistance Measure . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . | Culture DST . | gyr Seq . |
|---|---|---|---|---|---|---|---|---|
| S . | S . | R . | S . | S . | R . | R . | R . | |
| Poor outcome/total | 12/57 (21%) | 25/78 (28%) | 1/2 (50%) | 13/23 (57%) | ||||
Culture DST = resistant if moxifloxacin >0.5 mg/dL or if no moxifloxacin DST is available if levofloxacin DST shows resistance; gyr sequencing = resistant only if a high-level mutation is found as defined in the Methods.
Abbreviations: DST, drug susceptibility testing; R, resistant; S, sensitive; Seq, sequencing.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
